BioLife Solutions (BLFS) Misses Q3 EPS by 7c; Offers FY22 Revenue Guidance

BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.23), $0.07 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $40.7 million versus the consensus estimate of $42.02 million.

GUIDANCE:

BioLife Solutions sees FY2022 revenue of $160-164 million, versus the consensus of $163.4 million.

For earnings history and earnings-related data on BioLife Solutions (BLFS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c